2.870USD-1.71%Mkt Cap: 6.89M USDP/E: —Last update: 2026-06-01
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormo…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap6.89M USD
Enterprise Value6.55M USD
Revenue (TTM)3.00K USD
Gross Profit-1.44M USD
Net Income (TTM)-4.18M USD
Revenue/Share0.0010 USD
Last Price2.870 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees1
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.75
PEG0.58
EV/EBITDA-1.59
EV/Revenue2183.04
P/S2320.04
P/B2.24
EPS (TTM)-2.12
EPS (Forward)-0.60
52W Range
1.67026% of range6.200
52W High6.200 USD
52W Low1.670 USD
Profitability
Gross Margin0.00%
Oper. Margin-138166.67%
EBITDA Margin0.00%
Profit Margin-83520.00%
ROE-193.96%
ROA-140.80%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.87M USD
CapEx (TTM)98.00K USD
FCF Margin-71320.83%
FCF Yield-31.07%
Net Debt-354.00K USD
Net Debt/EBITDA0.09
Balance Sheet
Debt/Equity—
Current Ratio1.63
Quick Ratio0.59
Book Value/Sh1.271 USD
Cash/Share0.1460 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJul 18, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.44M
Float1.91M
Insiders14.03%
Institutions6.53%
Short Interest
Short Ratio0.7d
Short % Float0.35%
Short % Out.0.32%
Shares Short7.89K
Short (prev mo.)12.38K
Technical
SMA 502.769 (+3.7%)
SMA 2002.888 (-0.6%)
Beta-1.13
S&P 52W Chg27.70%
Avg Vol (30d)14.26K
Avg Vol (10d)22.54K
Technical Indicators
RSI (14)62.7
MACD-0.0043
MACD Signal-0.0677
MACD Hist.+0.0634
BB Upper2.902 USD
BB Middle2.583 USD
BB Lower2.264 USD
BB Width24.72%
ATR (14)0.1852 USD
Vol Ratio (20d)1.11x